Glaucoma

5-HTP is a direct serotonin precursor studied in multiple clinical trials for migraine prophylaxis. A placebo-controlled double-blind crossover study found favorable responses (>50% reduction in headache symptoms) in 52% of cases. A separate RCT showed 5-HTP was as effective as methysergide for migraine prevention. Doses of 400–600 mg/day have been evaluated in most trials.

Alpha-lipoic acid (ALA) has antioxidant and mitochondrial-supporting properties studied in migraine. A 2024 systematic review and meta-analysis of 5 RCTs (255 patients) found significant improvement in mean monthly migraine frequency with ALA as monotherapy or in combination. A 2022 double-blind RCT in 92 women showed significant reductions in migraine severity, frequency, and headache impact at 300 mg twice daily for 12 weeks.

Butterbur (Petasites hybridus) root extract had the highest level of evidence (Level A) for migraine prevention in the 2012 AAN/AHS guidelines, based on two RCTs. Its active sesquiterpenes (petasines) inhibit leukotriene biosynthesis, CGRP release, and prostaglandin synthesis. However, concerns about hepatotoxic pyrrolizidine alkaloids led AAN to withdraw its recommendation in 2015.

Caffeine has a dual role in migraine: low doses serve as an analgesic adjuvant and are present in several approved combination migraine treatments, while chronic high intake is associated with migraine chronification and medication-overuse headache. Caffeine abstinence has been shown in a prospective study to improve acute migraine treatment efficacy.

Intranasal capsaicin has been evaluated for migraine prevention via trigeminal desensitization. Clinical evidence is weaker than for cluster headache, classified as 'weaker scientific support' by PeaceHealth evidence database. A double-blind trial and case series support benefit, particularly for rhinogenic or sinus-associated migraine.

Intranasal capsaicin has been evaluated in clinical studies and case series for migraine treatment, with evidence of rapid pain relief via trigeminal CGRP depletion. Preliminary controlled study data and case series support efficacy, though large RCTs are lacking.

Intranasal capsaicin has been evaluated in controlled trials for cluster headaches (with double-blind support) and for migraines (with weaker evidence). Desensitisation of trigeminal sensory fibres is the proposed mechanism. PeaceHealth notes double-blind trial support for cluster headaches and weaker evidence for migraines.

CoQ10 is supported by Level C evidence (possibly effective) per AAN/AHS guidelines for migraine prevention. A 2024 meta-analysis of RCTs found CoQ10 decreased migraine frequency (MD = −1.73), severity (MD = −1.35), and duration (MD = −1.72). It is well tolerated with few adverse events.

Curcumin, the active polyphenol in turmeric, has been evaluated in RCTs for migraine. A double-blind placebo-controlled RCT found curcumin 500 mg twice daily for 8 weeks significantly reduced migraine attack duration and severity, and decreased serum CGRP levels. A meta-analysis of RCTs supported its role in migraine management.

DAO deficiency is significantly more prevalent in migraine patients than in healthy volunteers, and a randomized double-blind trial demonstrated that DAO supplementation reduced migraine headache duration by approximately 1.4 hours in DAO-deficient patients. Histamine promotes migraine via nitric oxide release from H1 receptor stimulation on intracranial arteries.

Feverfew (Tanacetum parthenium) has been used in European folk medicine for centuries to prevent migraines. Multiple RCTs and a 2020 Cochrane review (6 studies, 561 participants) found a reduction of approximately 0.6 migraine attacks per month versus placebo, though evidence quality is rated low. The AAN/AHS 2012 guidelines gave feverfew Level B evidence (probably effective).

Multiple RCTs and a 2025 dose-response meta-analysis of 12 trials (n=749) show that high-dose riboflavin (primarily 400 mg/day) significantly reduces migraine attack frequency and duration. The proposed mechanism involves FMN/FAD-dependent improvement of mitochondrial energy metabolism and reduction of oxidative stress in susceptible neurons.

A 2022 Frontiers in Neurology meta-analysis evaluated RCTs of gastrodin for migraine. Gastrodin modulates CGRP and adenosine A1 receptors in migraine models and crosses the blood-brain barrier. Multiple Chinese RCTs and pharmacopoeial preparations support this indication.

Ginger has been used traditionally for headache and nausea across Asian and Middle Eastern medicine systems. Clinically, a meta-analysis of RCTs concluded ginger is safe and effective for acute migraine treatment, with significant pain reduction at 2 hours. A double-blind placebo-controlled RCT (Cephalalgia, 2019) confirmed its acute efficacy when added to standard migraine treatment.

Ginkgo biloba, primarily via its terpene constituent ginkgolide B, has been studied for migraine with aura prophylaxis. Open clinical trials and preliminary studies suggest potential benefit, particularly for reducing aura frequency and duration. The 2019 PMC integrative migraine review identified positive results from older ginkgolide B studies.

Ginkgolide B, a terpene from Ginkgo biloba, has been studied for migraine with aura prophylaxis. An open multicenter trial in 50 women found significant reductions in aura frequency and duration over 4 months. Ginkgolide B acts as a platelet-activating factor (PAF) antagonist and modulates glutamate in the CNS, mechanisms relevant to migraine aura.

Small clinical studies and case series suggest kudzu may reduce migraine frequency and intensity, likely through its vasoactive effects on cerebral blood flow and anti-inflammatory properties. A 2017 retrospective study (Pucci et al., J Headache Pain) examined KUZIK® for migraine prophylaxis without aura. TCM also lists migraines as a traditional indication. Evidence remains preliminary.

Tryptophan metabolism is mechanistically linked to migraine via the serotonin and kynurenine pathways. Migraineurs have chronically lower serotonin levels between attacks, and tryptophan intake may influence serotonin homeostasis and migraine frequency. Both serotonin and kynurenine catabolites modulate trigeminal nociceptive processing relevant to migraine.

Lavender essential oil has clinical RCT evidence for acute migraine relief via aromatherapy. A placebo-controlled trial (European Neurology, 2012) found 15 minutes of inhaled lavender oil during a migraine attack produced significant reductions in headache severity versus placebo. A randomized clinical trial also evaluated lavender as prophylactic therapy for migraine.

Sartori's 1986 open study of lithium orotate in 42 alcoholic patients documented reduction and in some cases abolishment of migraine headaches as a secondary outcome. No dedicated migraine-specific RCT has evaluated lithium orotate. Evidence is limited to this single case series observation.

Magnesium is one of the most evidence-backed supplements for migraine prevention. AAN/AHS guidelines granted it Level B evidence (probably effective). A 2024 systematic review and meta-analysis found magnesium supplementation significantly reduced migraine attack frequency, severity, and monthly migraine days versus placebo. Intravenous magnesium is also used for acute migraine.

Melatonin has been studied in multiple RCTs for migraine prophylaxis, with most showing reductions in attack frequency, duration, and severity. A 2024 Nutraceuticals review characterized melatonin as weakly recommended, particularly for migraineurs with comorbid sleep disturbances, though evidence certainty is rated very low.

Topical menthol (10% solution or gel) has been studied in randomized trials as an abortive treatment for migraine without aura, demonstrating pain reduction, and relief of nausea and photophobia. Intranasal menthol application has also shown efficacy in preclinical migraine models.

Clinical trials have tested both topical and intranasal peppermint oil for acute migraine. A double-blind RCT in 120 migraine patients found intranasal peppermint oil comparable to lidocaine 4% for pain reduction. A 6% topical menthol gel also reduced migraine pain intensity at 2 hours.

Clinical and mechanistic evidence supports omega-3 fatty acids in migraine prevention via anti-neuroinflammatory and anti-nociceptive effects. EPA and DHA generate specialized pro-resolving mediators that modulate neuroinflammation implicated in migraine pathophysiology. RCTs have been conducted, and a completed clinical trial (NCT04572789) specifically evaluated omega-3 for migraine prevention.

Feverfew (Tanacetum parthenium) is the most clinically studied herbal remedy for migraine prophylaxis. Multiple RCTs and a Cochrane review support a modest reduction in attack frequency. Evidence is mixed across older trials but stronger with the stabilized MIG-99 CO2 extract. A 2025 meta-analysis of nine RCTs (899 participants) found a significant reduction in migraine frequency.

Topical peppermint oil (menthol-containing) has clinical RCT evidence for acute migraine headache relief. A 2010 study found a 10% menthol solution applied to forehead/temples was effective at terminating migraine pain and reducing nausea. A 2019 double-blind RCT found intranasal peppermint oil reduced headache intensity comparably to lidocaine treatment.

Petasines are the pharmacologically active sesquiterpene compounds (petasin and isopetasin) derived from butterbur (Petasites hybridus), directly responsible for its anti-migraine effects. They inhibit leukotriene biosynthesis, CGRP release, and nociceptive ion channels. Clinical evidence for migraine prevention is derived from trials using PA-free butterbur extract standardized to at least 15% petasines.

Early clinical research suggests that pine bark extract (Enzogenol) combined with vitamins E and C for 3 months reduces the severity and likelihood of migraine. The evidence is preliminary and based on a small study. Anti-inflammatory and vascular effects are proposed mechanisms.

Menstrual migraine is closely linked to premenstrual progesterone withdrawal, which destabilizes serotonin and GABA neurotransmitter systems. Early clinical reports by Dalton (1973) described successful treatment of menstrual migraine with progesterone suppositories. More recent evidence suggests nightly progesterone may help stabilize neurotransmitter fluctuations and prevent premenstrual migraine.

An open clinical trial published in PubMed (PMID 3514492) found that long-term administration of SAMe relieves pain in migraine sufferers, with benefits arising gradually over extended treatment. The proposed mechanism involves SAMe's role in modulating serotonin (5-HT) turnover, a key pathway in migraine pathophysiology. SAMe has been marketed in some European countries for migraine headaches since the mid-1980s. Evidence is limited to one small open trial; no placebo-controlled RCTs specific to migraine have been completed.

Serratiopeptidase is listed in clinical prescribing references as indicated for migraine headache, based on its anti-prostaglandin and bradykinin-hydrolyzing mechanisms. The AJPCR clinical applications review and multiple prescribing databases cite migraine as an SRP indication. No dedicated migraine RCT has been identified; evidence is based on clinical indication listings and anti-inflammatory mechanism overlap.

Neuroinflammation is a recognized mechanism in migraine pathogenesis, and SPMs target neuroinflammatory pathways relevant to migraine. Reduced plasma SPM levels have been observed in chronic migraine patients. SPMs inhibit CGRP-driven neurogenic inflammation and trigeminal sensitization in preclinical models.

Multiple RCTs and meta-analyses specifically evaluate Chuanxiong formulae in migraine patients. TMP/ligustrazine has been shown to inhibit trigeminovascular activation and reduce neurogenic inflammation central to migraine pathophysiology. A randomized double-blind placebo-controlled trial of Chuanxiong Qingnao Granule in migraine patients was conducted at China-Japan Friendship Hospital.

CoQ10 levels are frequently low in migraine sufferers, and multiple clinical trials show CoQ10 supplementation reduces migraine frequency, duration, and severity. Proposed mechanisms include improved mitochondrial function in neurons, reduction of neuroinflammatory CGRP, and antioxidant attenuation of oxidative stress that triggers migraine attacks. Ubiquinol is the preferred form due to superior bioavailability.

Vitamin B12 (cobalamin) contributes to migraine prevention through homocysteine-lowering methylation pathways. Combined supplementation with B12, B6, and folic acid has shown significant reductions in migraine severity and disability in RCTs. A large UK Biobank study found low B12 intake among the strongest correlates of migraine risk.

Riboflavin (Vitamin B2) is recommended for adult migraine prevention with Level B evidence per AAN/AHS guidelines. A 2024 meta-analysis of RCTs found riboflavin decreased migraine attack frequency (MD = −1.34). The standard prophylactic dose is 400 mg/day; adverse events are minimal (yellow discoloration of urine).

Niacin (vitamin B3) has a historical basis in migraine treatment; high-dose niacin causes vasodilation via prostaglandin release. A large UK Biobank prospective study found low B3 intake had among the strongest correlations with migraine risk. Inositol nicotinate (flush-free niacin) has also been studied in headache contexts.

Vitamin B6 (pyridoxine) has been studied for migraine prevention, primarily through its role in homocysteine metabolism and serotonin synthesis. An RCT found 80 mg/day pyridoxine for 12 weeks significantly reduced headache diary results, severity, and duration of migraine attacks versus placebo. Combination B6/B9/B12 therapy shows particularly consistent benefit.

Folate (vitamin B9), often combined with B6 and B12, has been studied for migraine prevention, particularly in patients with elevated homocysteine. RCTs combining folic acid 2 mg/day with B6 and B12 for 6 months significantly reduced migraine severity, disability, and homocysteine levels. Folic acid alone at lower doses showed less consistent benefit.

Vitamin D deficiency has been associated with higher migraine incidence. A 2024 systematic review and meta-analysis of RCTs found vitamin D supplementation reduced migraine frequency (MD = −1.69) and monthly migraine days (MD = −2.41). A 2020 RCT also found vitamin D3 combined with topiramate improved pediatric migraine prophylaxis versus topiramate alone.

The 1977 Bennett study and the Cheeke 2006 review (J Inflammation) note that yucca saponin supplementation was associated with a reduction in migraine headache incidence as a secondary finding. Drugs.com and traditional New Mexico healers list migraine as an oral use of yucca. The evidence is weak and not from a powered, primary migraine endpoint trial.

A 2019 animal study found that C. camphora essential oil suppressed pain-signaling pathways and weakened neurogenic inflammation relevant to migraine. Traditional Ayurvedic use of camphor for migraines is documented across centuries. Human clinical trial evidence is absent.

Devil's Claw appears in traditional and folk remedy references for migraine headache. It is listed among its historically recorded uses in indigenous southern African medicine and in compendium-style traditional medicine sources. No clinical trials have assessed it for migraine specifically.

Jamaican dogwood (Piscidia erythrina) is one of its primary traditional indications, used by Eclectic physicians and herbalists for migraine, particularly migraines with a nervous or vascular component. It is documented in herbal references including the British Herbal Pharmacopoeia. No human RCT evidence exists.

Dong Quai is listed in TCM and naturopathic sources as a traditional remedy for migraine, particularly those related to poor peripheral circulation and smooth muscle spasm. A. sinensis smooth muscle relaxant and vasodilatory properties are the proposed mechanisms. No human RCTs of Dong Quai monotherapy for migraine have been found.

Migraine (and neuralgia) are listed among the traditional therapeutic indications for C. speciosa in TCM texts and are cited in multiple peer-reviewed pharmacological reviews. No mechanistic pharmacological studies or clinical trials specifically addressing migraine have been identified.

Guarana's use for migraine is documented in Peruvian and broader Amazonian traditional medicine, with caffeine's vasoconstrictive properties providing a pharmacological rationale. It appears in multiple ethnobotanical records alongside headache treatment. No clinical trials specifically targeting migraine with guarana have been published.

IHN is cited in clinical sources including RxList and WebMD as used for migraines, particularly those linked to atherosclerosis or poor cerebrovascular circulation. However, Wikipedia explicitly states that migraine represents an indication with 'insufficient supporting evidence.' No RCTs specifically testing IHN for migraine prevention or treatment were identified.

Migraine is documented as a traditional indication for lemon balm in several historical sources and Iranian traditional medicine, with antispasmodic and COX/LOX-inhibiting mechanisms providing pharmacological plausibility. No controlled clinical trials targeting migraine have been published.

White willow bark (salicin) is listed among complementary treatments for migraine in several reference sources, and a pharmacokinetic observation documents that its metabolite salicylic acid can provide relief in acute migraine when absorption is enhanced. No dedicated migraine RCT exists for salicin alone.

Skullcap has traditional use for stress headaches and nervous pain, with TCM use of S. baicalensis for 'clearing heat' patterns that historically included head pain. Preclinical anti-inflammatory and serotonin 5-HT7 receptor activity is pharmacologically relevant to migraine pathophysiology. No direct clinical evidence for migraine prevention or treatment exists.

Valerian root has documented traditional use for migraine headache based on its CNS-calming and smooth muscle-relaxant properties. One small Iranian clinical study (Mirzaee et al., 2015) investigated valerian in migraine sufferers and reported positive findings, but this study has not been independently replicated and modern migraine management guidelines do not include valerian. The primary evidence base remains traditional.

White willow bark is listed by the German Commission E for headaches and has a long documented history for tension and vascular headaches including migraine. Its prostaglandin-inhibiting and analgesic properties are mechanistically relevant. Clinical evidence is described by authoritative sources as thinner than for back pain or arthritis, with no dedicated migraine RCTs identified.

Migraine is listed among the principal proposed uses of white willow by clinical evidence compilers (EBSCO Research Starters), and traditional Chinese medicine used willow to combat headache linked to excess heat or overactive inflammatory response. No RCT has specifically studied willow bark in migraine patients. The anti-inflammatory and COX-inhibitory mechanisms are pharmacologically relevant but clinical trial evidence in migraine is absent.

Traditional herbalists and the folk medical literature document wood betony as a specific remedy for migraine, attributed to its hypotensive glycosides and antispasmodic action on cerebral circulation. No clinical trial evidence exists.